

REFERENCES

1. Owen A. (2007). Coffee: The royal flush [Online]. Available at <http://curezone.com/art/read.asp?ID=29&db=5&C0=8182007> [2007, November 12].
2. Society AC. (2007). Colon therapy [Online]. Available at http://www.cancer.org/docroot/ETO/content/ETO_5_3X_Colon_Therapy.asp?sitearea=ETO. [2007, November 10].
3. Wikimedia Foundation. (2007). Colon hydrotherapy [Online]. Available at http://en.wikipedia.org/wiki/Colon_hydrotherapy [2007, November 1].
4. Azam S, Hadi N, Khan NU, Hadi SM. Antioxidant and prooxidant properties of caffeine, theobromine and xanthine. *Med Sci Monit* 2003;9(9):BR325–30.
5. Esposito F, Morisco F, Verde V, Ritieni A, Alezio A, Caporaso N, Fogliano V. Moderate coffee consumption increases plasma glutathione but not homocysteine in healthy subjects. *Aliment Pharmacol Ther* 2003;17(4):595-601.
6. Owen, Ana, *et al.* (2007). Caffeine dialysis process-coffee enema [Online]. Available at <http://curezone.com/art/read.asp?ID=30&db=5&C0=818> [2007, November 12].
7. Lam LT, Spamins VL, Wattenberg LW. Isolation and identification of kahweol palmitate and cafestol palmitate as active constituents of green coffee beans that enhance glutathione S-transferase activity in the mouse. *Cancer Res* 1982;42(4):1193-8.

8. No author. (2006). Coffee enema (Chicory-Free Coffee) [Online]. Available at <http://www.healthandyoga.com/html/enema/coffee-enema.html> [2007, November 18].
9. Richards DG, McMillin DL, Mein EA, Nelson CD. Colonic irrigations: a review of the historical controversy and the potential for adverse effects. *J Altern Complement Med* 2006;12(4):389–93.
10. บรรจบ ชุณหสวัตติกุล บรรณาธิการ. คู่มือการล้างพิษภาคปฏิบัติ. พิมพ์ครั้งที่ 3. กรุงเทพมหานคร: รวมทรรศน์; 2547 หน้า 37-52.
11. Kira S. (2004). Coffee, the great liver detoxifier?and the gall bladder connection [Online]. Available at <http://www.lifeforcetreats.com/news/2004/04/01/coffee-the-great-liver-detoxifier-and-the-gall-bladder-connection/> [2007, September 23].
12. Chuyen NV. Maillard reaction and food processing. Application aspects. *Adv Exp Med Biol* 1998;434:213–35.
13. Borrelli RC, Visconti A, Mennella C, Anese M, Fogliano V. Chemical characterization and antioxidant properties of coffee melanoidins. *J Agric Food Chem* 2002;50(22):6527-33.
14. Daglia M, Papetti A, Gregotti C, Berte F, Gazzani G. In vitro antioxidant and ex vivo protective activities of green and roasted coffee. *J Agric Food Chem* 2000;48(5):1449-54.
15. Shizuuchi S, Hayase F. Antioxidative activity of the blue pigment formed in a D-xylose-glycine reaction system. *Biosci Biotechnol Biochem* 2003;67(1):54-9.

16. Iwai K, Kishimoto N, Kakino Y, Mochida K, Fujita T. In vitro antioxidative effects and tyrosinase inhibitory activities of seven hydroxycinnamoyl derivatives in green coffee beans. *J Agric Food Chem* 2004;52(15):4893-8.
17. Cathy W. (2007). Coffee enemas [Online]. Available at <http://altmedicine.about.com/cs/dietarytherapy/a/EnemasColonics.htm>. [2007, May 5].
18. Owen, Ana, *et al.* (2007). Coffee enemas - description [Online]. Available at <http://curezone.com/art/read.asp?ID=31&db=5&C0=818> [2007, November 12].
19. Alexandra A. (2007). Coffee enema [Online]. Available at <http://www.ineedcoffee.com/01/01/enema/> 2007 [2007, April 27].
20. Helmenstine AM. (2007). Caffeine chemistry [Online]. Available at <http://chemistry.about.com/od/moleculescompounds/a/caffeine.htm> 2007 [2007, April 27].
21. Walter TM, Maheswari RU. (2006). Therapeutic uses of *Coffea Arabica*, Linn [Online]. Available at <http://openmed.nic.in/1545> [2007, November 18].
22. Graham DM. Caffeine-its identity, dietary source, intake and biological effects. *Nutri Rev* 1978;36(4):97-102.
23. Haller CA, Jacob P, Benowitz NL. Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. *Clin Pharmacol Ther* 2002;71(6):421-32.
24. Serafin WE. Drugs used in the treatment of asthma. In: Hardman JG, Limbird LE, Molinoff PB., *et al.* Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill companies Inc; 1996.p.672-9.

25. Wilkinson GR. In vivo probes for studying induction and inhibition of cytochrome P450 enzymes in human. In: Rodrigues AD, eds. Drug-drug interaction. Vol .116. New York: Marcel Dekker, Inc; 2002. p.68,449-50.
26. ชัยชาญ แสงดี, อุดม จันทรรักษ์ศรี บรรณาธิการ. แคลเฟอีน: Facts and issues. พิมพ์ครั้งที่ 1. กรุงเทพมหานคร: สมาคมเภสัชวิทยาแห่งประเทศไทย; 2540 หน้า: 22-29,49-53,78-81.
27. Benowitz NL. Clinical pharmacology of caffeine. *Annu Rev Med* 1990;41:277-88. Review.
28. Baselt RC, Cravey RH, eds. Disposition of toxic drugs and chemicals in man. 3rd ed. London: Year Book Medical Publishers, Inc; 1989. p. 120-2.
29. Fredholm BB, Batting K, Holmen J, Nehlig A, Zvrtau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. *Pharmacol Rev* 1999;51(1):83-133.
30. Parsons WD, Neims AH. Effects of smoking on caffeine clearance. *Clin Pharmacol Ther* 1978;24:40-5.
31. Wietholtz H, Zysset T, Marschall HU, Generat K, Matern S. The influence of rifampin treatment on caffeine clearance in healthy man. *J Hepatol* 1995;22(1):78-81.
32. Sawynok J, Yaksh TL. Caffeine as an analgesic adjuvant: A review of pharmacology and mechanisms of action. *Pharmacol Rev.* 1993;45(1):45-60.
33. Aldridge A, Aranda JV, Neims AH. Caffeine metabolism in the newborn. *Clin Pharmacol Ther.* 1979;25(4):447-52.

34. Lee C. Antioxidant ability of caffeine and its metabolites based on the study of oxygen radical absorbing capacity and inhibition of LDL peroxidation. *Clin Chim Acta* 2000;295(1-2):141- 54.
35. Ullrich D, Compagnone D, Miinch B, Brandes A, Hille H, Bircher J. Urinary caffeine metabolites in man : Age - dependant changes and pattern in various clinical situations. *Eur J Clin Pharmacol* 1992;43(2):167-72.
36. Fisone G, Borgkvist A, Usiello A. Caffeine as a psychomotor stimulant: mechanism of action. *Cell Mol Life Sci* 2004;61(7-8):857-72.
37. Cada DJ, Fashp F, Covington TR, et al., eds. *Drug facts and comparisons*. 57th ed. Missouri: Wolters Kluwer Company; 2003. p. 835-7.
38. Jung RT, Shetty PS, James WPT, Barrand MA, Callingham BA. Caffeine: its effect on catecholamines and metabolism in lean and obese humans. *Clin Sci* 1981;60:527-35.
39. Shi X, Dalal NS, Jain AC. Antioxidant behaviour of caffeine: efficient scavenging of hydroxyl radicals. *Food Chem Toxicol* 1991;29:1-6.
40. Mathew RJ, Wilson WH. Caffeine induced changes in cerebral circulation. *Stroke* 1985;16(5):814-17.
41. Laska EM, Sunshine A, Zigelboim I, Roure C, Marrero I, Wanderling J, Olson N. Effect of caffeine on acetaminophen analgesia. *Clin Pharmacol Ther* 1983;33(4):498-509.
42. Onrot J, Goldberg MR, Biaggioni I, Hollister AS, Kingaid D, Robertson D. Hemodynamic and humoral effects of caffeine in autonomic failure. *N Engl J Med* 1985;313(9):549-54.

43. Shapira B, Lerer B, Gilboa D, Drexler H, Kugelmass S, Calev A. Facilitation of ECT by caffeine pretreatment. *Am J Psychiatry* 1987;144:1199-292.
44. Higdon JV, Frei B. Coffee and health: a review of recent human research. *Crit Rev Food Sci Nutr* 2006;46(2):101-23. Review.
45. Mackay DC, Rollins JW. Caffeine and caffeinism. *J R Nav Med Serv* 1989;75(2):65-7.
46. Teare JP, PUNCHARD NA, POWELL JJ, LUMB PJ, MITCHELL WD, THOMPSON RPH. Automated spectrophotometric method for determining oxidized and reduced glutathione in liver. *Clin chem* 1993;39(4):686-9.
47. Kerrigan S, Lindsey T. Fatal caffeine overdose: two case reports. *Forensic Sci Int* 2005;153(1):67-9.
48. Carrillo JA, Benitez J. Clinically significant pharmacokinetic interactions between dietary caffeine and medications. *Clin Pharmacokinet* 2000;39(2):127-53. Review.
49. Bichler J, Cavin C, Simic T, Chakraborty A, Ferik F, Hoelzl C, Schulte-Hermann R, Kundi M, Haidinger G, Angelis K, Knasmuller S. Coffee consumption protects human lymphocytes against oxidative and 3-amino-1-methyl-5H-pyrido[4,3-b] indole acetate (Trp-P-2) induced DNA-damage: Results of an experimental study with human volunteers. *Food Chem Toxicol* 2007;45(8):1428-36.
50. Huber WW, Prustomersky S, Delbanco E, Uhl M, Scharf G, Turesky RJ, Thier R, Schulte-Hermann R. Enhancement of the chemoprotective enzymes glucuronosyl transferase and glutathione transferase in specific organs of the rat

by the coffee components kahweol and cafestol. Arch Toxicol 2002;76(4):209-17.

51. Coles B, Ketterer B. The role of glutathione and glutathione S-transferases in chemical carcinogenesis. Crit Rev Biochem Mol Biol 1990;25(1):47-70.
52. Huber WW, Scharf G, Rossmannith W, Prustomersky S, Grasl-Kraupp B, Peter B, Turesky RJ, Schulte-Hermann R. The coffee components kahweol and cafestol induce γ -glutamylcysteine synthetase, the rate limiting enzyme of chemoprotective glutathione synthesis, in several organs of the rat. Arch Toxicol 2002;75(11-12):685-94.
53. Huber WW, Teitel CH, Coles BF, King RS, Wiese FK, Kaderlik KR, Casciano DA, Shaddack JG, Mulder GI. Potential chemoprotective effects of the coffee components kahweol and cafestol palmitates via modification of hepatic N-acetyltransferase and glutathione S-transferase activities. Environ Mol Mutagen 2004;44(4):265-76.
54. Scharf G, Prustomersky S, Knasmuller S, Schulte-Hermann R, Huber WW. Enhancement of glutathione and γ -glutamylcysteine synthetase, the rate limiting enzyme of glutathione synthesis, by chemoprotective plant-derived food and beverage components in the human hepatoma cell line HepG2. Nutr Cancer 2003;45(1):74-83.
55. Olthof MR, Hollman PC, Zock PL, Katan MB. Consumption of high doses of chlorogenic acid, present in coffee, or of black tea increases plasma total homocysteine concentrations in humans. Am J Clin Nutr 2001;73(3):532-8.

56. Natella F, Nardini M, Giannetti I, Dattilo C, Scaccini C. Coffee drinking influences plasma antioxidant capacity in humans. *J Agric Food Chem* 2002;50(21):6211-6.
57. Olthof MR, Hollman PC, Zock PL, Katan MB. Consumption of high doses of chlorogenic acid, present in coffee, or of black tea increases plasma total homocysteine concentrations in humans. *Am J Clin Nutr* 2001;73(3):532-8.
58. Grubben MJAL, Van den Braak CCM, Broekhuizen R, De Jong R, Van Rijt L, De Ruijter E, Peter WH, Katan MB, Nagengast FM. The effect of unfiltered coffee on potential biomarkers for colonic cancer risk in healthy volunteers: a randomized trial. *Aliment Pharmacol Ther* 2000;14(9):1181-90.
59. Yukawa GS, Mune M, Otani H, Tone Y, Liang X-M, Iwahashi H, Sakamoto W. Effects of coffee consumption on oxidative susceptibility of low-density lipoproteins and serum lipid levels in humans. *Biochemistry (Mosc)* 2004;69(1):70-4.
60. Steinkellner H, Hoelzl C, Uhl M, Cavin C, Haidinger G, Gsur A, Schmid R, Kundi M, Bichler J, Knasmuller S. Coffee consumption induces GSTP in plasma and protects lymphocytes against (\pm)-anti-benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide induced DNA-damage: Results of controlled human intervention trials. *Mutat Res* 2005;591(1-2):264-75.
61. Gutteridge JM. Lipid peroxidation and antioxidants as biomarkers of tissue damage. *Clin Chem* 1995;41(12 Pt 2):1819-28. Review.
62. Halliwell B, Chirico S. Lipid peroxidation: its mechanism, measurement and significance. *Am J Clin Nutr* 1993;57(5 Suppl):715S-724S; discussion 724S-725S. Review.

63. Tanaka E. Simultaneous determination of caffeine and its primary demethylated metabolites in human plasma by high-performance liquid chromatography. *J Chromatogr* 1992;575(2):311-4.
64. Schreiber-Deturmeny E, Bruguerolle B. Simultaneous high-performance liquid chromatographic determination of caffeine and theophylline for routine drug monitoring in human plasma. *J Chromatogr B* 1996;677:305-12.
65. Ellman GL. Tissue sulfhydryl group. *Arch Biochem Biophys*. 1959;82:70-7.
66. Smith JB, Ingerman CM, Silver MJ. Malondialdehyde formation as an indicator of prostaglandin production by human platelets. *J Lab Clin Med* 1976;88:167-72.
67. Re R, Pellegrini N, Proteggente A, Pannala A, Yang M, Rice-Evans C. Antioxidant activity applying an improved ABTS radical cation decolorization assay. *Free Radic Biol Med* 1999;26:1231-7.
68. Kasap S, Gönenç A, Şener DE, Hisar İ. Serum Cardiac Markers in Patients with Acute Myocardial Infarction: Oxidative Stress, C-Reactive Protein and N-Terminal Probrain Natriuretic Peptide. *J Clin Biochem Nutr* 2007;41:50-7.
69. Arnaud MJ. The pharmacology of caffeine. *Prog Drug Res*.1987;31:273-313.
70. Bonati M, Latini R, Galetfi F, Young JF, Tognoni G, Garattini S. Caffeine disposition after oral doses. *Chin Pharmacol Ther*. 1982;32:98-106.
71. Nehig A. Are we dependent upon coffee and caffeine? A review on human and animal data. *Neurosci and biochem Rev*. 1999;23:563-5.
72. Grab FL, Reinstein JA. Determination of caffeine in plasma by gaschromatography. *J Pharm Sci*. 1968;57::1703-6.

73. Blanchard J, Sawers SJA. The absolute bioavailability of caffeine in man. *Eur J Clin Pharmacol*. 1983;24:93-8.
74. Gerald KM. *AHFS Drug Information*. Bethesda: American Society of Hospital Pharmacist, 1990.p.661-3
75. Gerson Institute (2004). *Gerson Therapy* [Online]. Available: www.gerson.org [2009, January 28].
76. Johnson L, Barrett KE. Digestion and absorption. *Physiology of the gastrointestinal tract*. 4th ed. Academic press, 2006.p.2325-28
77. Axelrod J, Reichenenthal J. The fate of caffeine in man and a method for its estimation in biological material. *J Pharmacol Exp Ther* 1953;107:519-23.
78. Cook CE, Tallent CR, Amerson EW, Myers MW, Kepler JA, Taylor GF, et al. Caffeine in plasma and saliva by a radioimmunoassay procedure. *J Pharmacol Exp Ther* 1976;199:679-86.
79. Astrup A, Toubro S, Cannon S, Pia Hem LB, Madsen J. Caffeine: a double-blind, placebo-controlled study of its thermogenic, metabolic, and cardiovascular effects in healthy volunteers. *Am J Clin Nutr* 1990;51:759-67.
80. Casiglia E, Paleari CD, Petucco S, Bongiovì S, Colangeli G, Baccilieri MS, et al. Haemodynamic effects of caffeine in normal volunteers: A placebo-controlled clinical study. *J Int Med* 1991;229:501-4.
81. Casiglia E, Paleari CD, Petucco S, Bongiovì S, Colangeli G, Baccilieri MS, et al. Haemodynamic effects of coffee and purified caffeine in normal volunteers: a placebo-controlled clinical study. *J Hum Hypertens* 1992;6:95-9.

82. Newcombe PF, Renton KW, Rautaharju PM, Spencer A, Montague TJ. High dose of caffeine and cardiac rate and rhythm in normal subjects. *Chest* 1988;94(1):90-4.
83. Theoharides CT, eds. *Essential of pharmacology*. 2nd ed. New York: Little, Brown Company;1996.p.26-8.
84. Trine R, Bente H. Coffee consumption and human health - beneficial or detrimental? - Mechanisms for effects of coffee consumption on different risk factors for cardiovascular disease and type 2 diabetes mellitus. *Mol Nutr Food Res* 2005;49:274 - 84.
85. Ascherio A, Zhang SM, Hernan MA. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. *Ann Neurol* 2001;50:56-63.
86. La Vecchia C. Coffee, liver enzymes, cirrhosis and liver cancer. *J Hepatol* 2005;42:444-6.
87. Salazar-Martinez E, Willett WC, Ascherio A, et al. Coffee consumption and risk for type 2 diabetes mellitus. *Ann Intern Med* 2004;140:1-8.
88. Michelle M, Louise L, Paul L. Red wine consumption increases antioxidant status and decreases oxidative stress in the circulation of both young and old humans. *Nutr J* 2007;6:27.
89. Yanagimoto K, Ochi H, Lee KG, Shibamoto T. Antioxidative activities of fractions obtained from brewed coffee. *J Agric Food Chem* 2004;52:592-6.
90. Barbaro G, Di Lorenzo G, Soldini M, et al. Hepatic glutathione deficiency in chronic hepatitis C: quantitative evaluation in patients who are HIV positive and HIV negative and correlations with plasmatic and lymphocytic concentrations and with the activity of liver disease. *Am J Gastroenterol* 1996; 91:2569-73.

91. Devasagayam TP, Kamat JP, Mohan H, Kesavan PC. Caffeine as an antioxidant: inhibition of lipid peroxidation induced by reactive oxygen species. *Biochim Biophys Acta* 1996;1282: 63 -70.
92. Johnston KL, Clifford MN, Morgan LM. Coffee acutely modifies gastrointestinal hormone secretion and glucose tolerance in humans: glycemic effects of chlorogenic acid and caffeine. *Am J Clin Nutr* 2003;78:728 -33.
93. Arias IM, Jakoby WB, editors. *Glutathione: Metabolism and function*. New York: Raven Press; 1976.
94. Baillie TA, Slatter JG. Glutathione: A vehicle for the transport of chemically reactive metabolites in vivo. *Acc Chem Res* 1991;24:264-70.
95. Lash LH, Jones DP. Distribution of oxidized and reduced forms of glutathione and cysteine in rat plasma. *Arch Biochem Biophys* 1985;240:583-92.
96. Wendel A, Cikryt P. The level and half-life of glutathione in human plasma. *FEBS Lett* 1980;120:209-11.
97. Morrison JA, Jacobsen DW, Sprecher DL, Robinson K, Khoury P, Daniels SR. Serum Glutathione in Adolescent Males Predicts Parental Coronary Heart Disease. *Circulation* 1999;100(22):2244-7.
98. Armstrong D, Browne R. The analysis of free radicals, lipid peroxides, antioxidant enzymes and compounds to oxidative stress as applied to the clinical chemistry laboratory. *Adv Exp Med Biol* 1994;366:43-58
99. Yagi KS. Simple assay for the level of total lipid peroxides in serum or plasma. *Methods in Molecular Biology*. 1998;108:101-6.

100. Berg vd, R.M.M.Haenen G, Berg Hvd, Vijgh Wvd, Bast A. The predictive value of the antioxidant capacity of structurally related flavonoids using the Trolox equivalent antioxidant capacity (TEAC) assay. *Food Chem* 2000;70:391-5.
101. Ozdemir G, Ozden M, Maral H, Kuskay S, Cetinalp P, Tarkun I. Malondialdehyde, Glutathione, Glutathione Peroxidase and Homocysteine Levels in Type 2 Diabetic Patients With and Without Microalbuminuria. *Ann Clin Biochem* 2005;42(Pt2):99-104.
102. Olcina GJ, Muñoz D, Timón R, Caballero MJ, Maynar JI, Córdova A, et al. Effect of caffeine on oxidative stress during maximum incremental exercise. *Journal of Sports Science and Medicine* 2006;5:621-8
103. Valabhji J, McColl AJ, Richmond W, Schachter M, Rubens MB, Elkeles RS. Total Antioxidant Status and Coronary Artery Calcification in Type 1 Diabetes. *Diabetes Care* 2001;24(9):1608-13.
104. Torun AN, Kulaksizoglu S, Kulaksizoglu M, Pamuk BO, Isbilen E, Tutuncu NB. Serum total antioxidant status and lipid peroxidation marker malondialdehyde levels in overt and subclinical hypothyroidism. *Clin Endocrinol* 2009;70:469-74.
105. Díaz-Rubio M E, Saura-Calixto F. Dietary Fiber in Brewed Coffee. *J Agric Food Chem* 2007;55(5):1999-2003.
106. Cano CP, Bermúdez VP, Atencio HE, Medina MT, Anilsa A, Souki A, et al. Increased serum malondialdehyde and decreased nitric oxide within 24 hours of thrombotic stroke onset. *Am J Ther* 2003;10(6):473-6.